Interestingly, the administration of an anti-TNF-α monoclonal antibody (infliximab) significantly reduces the clinical symptoms and radiographic and clinical progression of bone loss in both rheumatoid arthritis (human model) and periodontal disease (primate model)50, 51. This evidence concerns the gene TNF and periodontal disorder.